Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

by C. Orkin, E. Dejesus, H. Khanlou, A. Stoehr, K. Supparatpinyo, E. Lathouwers, E. Lefebvre, M. Opsomer, T. Van de Casteele, F. Tomaka
Published 2018

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

by C. Orkin, E. Dejesus, H. Khanlou, A. Stoehr, K. Supparatpinyo, E. Lathouwers, E. Lefebvre, M. Opsomer, T. Van de Casteele, F. Tomaka
Published 2018

Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study

by Gareth Tudor-Williams, Pedro Cahn, Kulkanya Chokephaibulkit, Jan Fourie, Chris Karatzios, S. Dincq, M. Opsomer, T. N. Kakuda, S. Nijs, L. Tambuyzer, F. L. Tomaka, Rosa Bologna, Esaú João, José Henrique Pilotto, Marisa Mussi-Pinhata, Jorge Pinto, Normand Lapointe, Albert Faye, Kamila Kebaili, Steven Welch, Stefania Bernardi, Luisa Galli, Carlo Giaquinto, Nicola Principi, Gian Vincenzo Zuccotti, Henriette J. Scherpbier, Laura Marques, Isabel Soares, Margarida Tavares, Midnela Acevedo, Dan Duiculescu, Sorin Rugina, Gulam H. Latiff, Claudia Fortuny, Juan Antonio Leon Leal, Marissa Navarro, Jose T. Ramos, Tawee Chotpitayasunondh, Pope Kosalaraksa, Kiat Ruxrungtham, Jacobo Abadi, Tess Barton, William Borkowsy, Janet Chen, Joseph Church, Patricia Flynn, Sohail Rana, Richard Rutstein, Leonard Weiner
Published 2018